http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003017148-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6420d04b0d68f339771080e32bd0fbc9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-48 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-63 |
| filingDate | 2001-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd11cfcc761463b767b9f81fbb8227fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_616ef6a7011f73298f15048aeee15cdc |
| publicationDate | 2003-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2003017148-A1 |
| titleOfInvention | Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity |
| abstract | Insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease believed to be caused by an inflammatory process in the pancreas leading to selective destruction of the β cells. Inducible cyclooxygenase (COX-2) is expressed under inflammatory conditions and its product prostaglandin E 2 (PGE 2 ) is an important inflammation mediator. Administration of the selective COX-2 inhibitor such as, e.g., NS-398 prevents the onset of diabetes in mice brought on by multiple low-doses of streptozotocin (STZ). Histological observations indicated that STZ-mediated destruction of β cells was prevented by NS-398 treatment. Delayed (day 3) administration of NS-398 was also protective in this model. These results demonstrate the critical importance of COX-2 activity in autoimmune destruction of β cells, and point to the fact that COX-2 inhibition should provide a preventive therapy against IDDM or other autoimmune problems, including allograft rejection. Inhibitors of NF-κB activation may also be used to prevent IDDM and allograft rejection. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8975228-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012038251-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3338773-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103648530-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2433629-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112999232-A |
| priorityDate | 2000-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 429.